Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Selective estrogen receptor modulator. Estrogen agonist in bone receptors and estrogen antagonist in breast and uterine tissue. Indicated for the treatment of osteoporosis and prevention of breast cancer. Oral administration once a day.
At the date of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of protein binding) make it unlikely that significant amounts will pass into breast milk.
Its low oral bioavailability makes it difficult for it to pass into the infant's plasma from ingested breast milk, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Raloxifene does not alter prolactin secretion in premenopausal women, but it does increase levels of oestradiol and sex hormone-binding globulin (SHBG). (Faupel 2006)